Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Transcytosis of IgG

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cancer prevalence and care disparities among individuals with intellectual disabilities: a cross-sectional pan-cancer analysis.

ESMO real world data and digital oncology·2026

Same author

German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus-version 4.0.

ESMO gastrointestinal oncology·2026

Same author

Changes in survival of >3800 patients with metastatic colorectal cancer in Germany: results from a 16-year prospective longitudinal real-world data analysis.

ESMO real world data and digital oncology·2026

Same author

Self-reported financial difficulties of colorectal cancer patients 1 year after start of treatment.

ESMO open·2025

Same author

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

The German Network for Personalized Medicine to enhance patient care and translational research.

Nature medicine·2023

Search research articles

Related Experiment Video

Updated: May 30, 2026

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Published on: May 21, 2015

[Pregnancy under immunosuppression].

J Walldorf¹, M M Dollinger, T Seufferlein

¹Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Halle, Ernst-Grube-Straße 40, 06120, Halle, Deutschland. Jens.Walldorf@medizin.uni-halle.de

|July 28, 2011

Summary

For patients desiring children, understanding immunosuppressant risks during pregnancy is crucial for maternal and infant safety. An interdisciplinary approach ensures effective treatment and healthy outcomes.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic Poly(I:C)

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic Poly(I:C)

Published on: March 25, 2016

Related Experiment Videos

Last Updated: May 30, 2026

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Published on: May 21, 2015

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic Poly(I:C)

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic Poly(I:C)

Published on: March 25, 2016

Area of Science:

Immunology
Pharmacology
Obstetrics

Context:

Managing immunosuppression in patients with fertility desires and during pregnancy presents unique challenges.
Balancing effective immunosuppressive therapy with the goal of a healthy pregnancy and child is paramount.

Purpose:

To review the risks associated with commonly prescribed immunosuppressants during pregnancy.
To inform treatment decisions for immunosuppressed patients planning pregnancy or who are pregnant.

Summary:

This review discusses the safety of frequently used immunosuppressants for both mother and child during and after pregnancy.
It highlights the importance of understanding specific drug risks to optimize therapy and ensure favorable pregnancy outcomes.
An interdisciplinary approach is recommended for comprehensive patient care.

Impact:

Provides essential information for clinicians managing immunosuppressed patients with reproductive aspirations.
Aids in counseling patients regarding the risks and benefits of immunosuppressive therapy during pregnancy.
Contributes to improved maternal and infant health outcomes in this vulnerable population.